Viridian Therapeutics (VRDN) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- -$1.05
- Estimate
- -$1.03
- Surprise
- -2.3%
- Revenue (period 2026-06-30)
- $284,000
- Score today
- 4.8/10
Revenue source: xbrl.
How the report landed
Viridian Therapeutics (VRDN) reported a wider loss than forecast — adjusted EPS of -$1.05 against the -$1.03 estimate (a 2.3% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates VRDN Sell at 4.8/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's -2.3% surprise compares with a +17.5% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- Concentration risk — Pipeline: veligrotug
- Quality below floor (1.8 < 4.0)
- Value-trap signals (3/5): Margin compression (op margin -81.6%), High leverage (D/E 1.7), Negative free cash flow
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $20.32
- Price target
- $33.08
- Stop
- $19.62
- Upside to target
- +62.8%
- Reward-to-risk
- 6.7:1
Model outputs from TrendMatrix’s engine as of 2026-09-24 — shown for context, not personalized investment advice.
VRDN at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $2.43B
- P/E (fwd)
- -7.8
- 52-week range
- $13.18–$34.29
- Off 52-week high
- 40.8%
- RSI (14)
- 32
- Volume vs avg
- 0.61×
- Score today
- 4.8/10